All In Biotech

Drug Trial Radar · NCT06429722

To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.

A Phase 2a, Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With a Major Depressive Episode Associated With Bipolar II Disorder

Last checked: Nov 20, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

May 13, 2024

Primary completion

Apr 9, 2025

Study completion May 30, 2025

Sponsor

Lead sponsor
Neumora Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled pilot study aiming to evaluate the effects of NMRA-335140 on symptoms of major depression in adults with Bipolar (BP) II disorder. The study design consists of a Screening Period (up to 28 days), a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo), and a 6-week Safety Follow-up Period.

Conditions

  • Major Depressive Episode Associated With Bipolar II Disorder

Interventions

  • NMRA-335140 80 mgDrug

    Participants will receive NMRA-335140 at a dose of 80 mg QD, orally.

  • PlaceboDrug

    Placebo will be administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline to Week 6 in the Montgomery-Asberg Depression Rating Scale (MADRS) total scoreTime frame: Baseline and up to Week 6

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Neumora Investigator Site

    Phoenix, Arizona

  • Neumora Investigator Site

    Little Rock, Arkansas

  • Neumora Investigator Site

    Garden Grove, California

  • Neumora Investigator Site

    Long Beach, California

  • Neumora Investigator Site

    San Jose, California

  • Neumora Investigator Site

    Torrance, California

  • Neumora Investigator Site

    Gainesville, Florida

  • Neumora Investigator Site

    Lauderhill, Florida

  • Neumora Investigator Site

    Maitland, Florida

  • Neumora Investigator Site

    Miami, Florida

  • Neumora Investigator Site

    Miami Lakes, Florida

  • Neumora Investigator Site

    Marietta, Georgia

  • Neumora Investigator Site

    Savannah, Georgia

  • Neumora Investigator Site

    Watertown, Massachusetts

  • Neumora Investigator Site

    Flowood, Mississippi

  • Neumora Investigator Site

    Marlton, New Jersey

  • Neumora Investigator Site

    Princeton, New Jersey

  • Neumora Investigator Site

    Toms River, New Jersey

  • Neumora Investigator Site

    Brooklyn, New York

  • Neumora Investigator Site

    Houston, Texas

  • Neumora Investigator Site

    Bellevue, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.